CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus Invasive Coronary Physiology After Stent Implantation: Another Step Toward Precision Medicine Proportion and Morphological Features of Restenosis Lesions With Acute Coronary Syndrome in Different Timings of Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation Right ventricular stroke work correlates with outcomes in pediatric pulmonary arterial hypertension European Bifurcation Club White Paper on Stenting Techniques for Patients With Bifurcated Coronary Artery Lesions Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction Dynamic atrioventricular delay programming improves ventricular electrical synchronization as evaluated by 3D vectorcardiography Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes
|<<... 44 45 46 47 48 49 50 ...>>|

Clinical Trial2019 May 14;40(19):1553-1562.

JOURNAL：Eur Heart J. Article Link

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial

Oldgren J, Steg PG, Hohnloser SH et al. Keywords: atrial fibrillation with PCI history; dabigatran with P2Y12 inhibitor vs warfarin with P2Y12 inhibitor and aspirin; major bleeding

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top